Physician profile
Manjunath Markandaya
NPI 1215101514
$11,781.20
in general payments reported to CMS, 2019-2025
15 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $968 · 2020: $3,434 · 2021: $6,431 · 2022: $925 · 2024: $22.87.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $22.87.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $22.87 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $6,465.81 | 2019-2022 | |
| Portola Pharmaceuticals, LLC | $2,898.54 | 2019-2020 | |
| Penumbra, INC. | $575.48 | 2019-2021 | |
| Astrazeneca Pharmaceuticals LP | $461.65 | 2021-2022 | |
| Medtronic USA, INC. | $394.75 | 2019-2020 | |
| Irras USA, INC. | $359.92 | 2020-2021 | |
| Depuy Synthes Sales INC. | $195.78 | 2019 | |
| Baxter Healthcare | $130.88 | 2019 | |
| La Jolla Pharmaceutical Company | $124.84 | 2019-2020 | |
| Chiesi USA, INC. | $79.40 | 2019 | |
| Ucb, INC. | $27.74 | 2019-2021 | |
| Laborie Medical Technologies Corp. | $22.87 | 2024 | Endosheath Technology |
| Allergan, INC. | $17.88 | 2019 | |
| Csl Behring | $13.87 | 2020 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $11.79 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Manjunath Markandaya listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.